Amgen Releases 8th Edition of Biosimilar Trends Report

THOUSAND OAKS, Calif.: THOUSAND OAKS, Calif., Sept. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today released the 8th edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feature considers how advancements in biosimilars can...

Click to view original post